ArticleBMC infectious diseases2025
When public health emergencies hit the front line: a qualitative study of the patient experience in the emergency department and outpatient infectious disease clinic during the 2022 Mpox clade IIb outbreak.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe World Health Organization (WHO) declared mpox clade IIb a Public Health Emergency of International Concern (PHEIC) in July 2022. During the clade IIb epidemic, patients presented to both Emergency Departments (ED) and Infectious Disease (ID) clinics for care. Given the uncertainty and limited knowledge of mpox in 2022, we sought to understand the patient experience to inform service delivery for future outbreaks.
methodsA retrospective qualitative study enrolled patients who presented to five EDs and one ID clinic in the Johns Hopkins Health System who tested positive for mpox virus (MPXV) between June 1 and December 31, 2022. Patient interviews were conducted in pairs with one researcher as the interviewer and a second as note-taker. A semi-structured interview guide with post-interview coding for content analysis was used to ascertain clinical factors, individual factors, and system factors that impacted the patient experience.
resultsOf 73 patients who tested positive for MPXV, 47 (64.4%) presented to EDs and 26 (35.6%) to the ID clinic; 23 (31.5%) agreed to participate [n = 13 ED, 27.7%; n = 10 ID, 38.5%]. All identified as male, median age was 36 years [IQR 31-41], 65.2% Black [n = 7 ED, 53.8%; n = 7 ID, 70.0%], 87.0% men who have sex with men [n = 10 ED, 76.9%; n = 10 ID, 100%], 69.6% were people living with HIV [n = 7 ED, 53.8%; n = 9 ID, 90.0%]. Participants diagnosed in EDs perceived difficulties with follow up and isolation, desired more information about tecoviromat, and nearly half reported no contact from local health departments for follow up care or tecoviromat access. Participants presenting to the ID clinic endorsed positive experiences tied to an established and trusted medical home. Stigma, loneliness, and mental health difficulties were consistent themes for all participants.
conclusionPatients present to various venues for infectious diseases such as mpox. Many present to EDs as a safety net service or for more severe disease manifestations. Institutional partnerships between ED, ID, and public health authorities, ongoing training, an on-call system for infectious disease threats, de-stigmatization, and focus on successful linkage-to-care pathways are potential ways to improve responses for future novel infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.